IKT Inhibikase Therapeutics Inc

Price (delayed)

$1.66

Market cap

$219.17M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.43

Enterprise value

$169.6M

?
Relative Growth: Rel. Growth: 13
Relative Strength: Rel. Strength: 35
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 4

Inhibikase is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders that arise inside and outside of the brain. Inhibikase is headquartered in Atlanta, Georgia with additional ...

Highlights
IKT's quick ratio has surged by 174% year-on-year and by 38% since the previous quarter
The company's debt has shrunk by 100% YoY
The equity has soared by 96% year-on-year but it has declined by 3.1% since the previous quarter
Inhibikase Therapeutics's net income has decreased by 39% YoY and by 6% from the previous quarter

Key stats

What are the main financial stats of IKT

IKT stock price

How has the Inhibikase Therapeutics stock price performed over time
Intraday
-0.6%
1 week
-6.21%
1 month
-14.43%
1 year
-16.16%
YTD
-19.02%
QTD
-1.19%

Financial performance

How have Inhibikase Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$55.8M
Net income
-$50.96M
Gross margin
N/A
Net margin
N/A
Inhibikase Therapeutics's operating income has decreased by 41% YoY and by 4.6% from the previous quarter
Inhibikase Therapeutics's net income has decreased by 39% YoY and by 6% from the previous quarter

Price vs fundamentals

How does IKT's price correlate with its fundamentals

Growth

What is Inhibikase Therapeutics's growth rate over time

Valuation

What is Inhibikase Therapeutics stock price valuation
P/E
N/A
P/B
1.31
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 27% YoY and by 12% from the previous quarter
The equity has soared by 96% year-on-year but it has declined by 3.1% since the previous quarter
The stock's price to book (P/B) is 10% more than its 5-year quarterly average of 1.2 but 6% less than its last 4 quarters average of 1.4

Efficiency

How efficient is Inhibikase Therapeutics business performance
IKT's return on invested capital has surged by 62% year-on-year and by 54% since the previous quarter
IKT's return on equity is up by 48% year-on-year and by 12% since the previous quarter
The return on assets is up by 45% year-on-year and by 10% since the previous quarter

Dividends

What is IKT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IKT.

Financial health

How did Inhibikase Therapeutics financials performed over time
IKT's quick ratio has surged by 174% year-on-year and by 38% since the previous quarter
Inhibikase Therapeutics's current ratio has surged by 174% YoY and by 39% QoQ
The company's debt is 100% lower than its equity
The company's debt has shrunk by 100% YoY
The equity has soared by 96% year-on-year but it has declined by 3.1% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.